2001
Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum−Spermidine Species through Hydrolytic Cleavage of Carbamates
Hegmans A, Qu Y, Kelland L, Roberts J, Farrell N. Novel Approaches to Polynuclear Platinum Pro-Drugs. Selective Release of Cytotoxic Platinum−Spermidine Species through Hydrolytic Cleavage of Carbamates. Inorganic Chemistry 2001, 40: 6108-6114. PMID: 11703107, DOI: 10.1021/ic010509a.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCarbamatesCatalysisChromatography, High Pressure LiquidFemaleHumansHydrogen-Ion ConcentrationHydrolysisInhibitory Concentration 50Leukemia L1210MiceMolecular StructureNuclear Magnetic Resonance, BiomolecularOrganoplatinum CompoundsOvarian NeoplasmsPolyaminesProdrugsSpermidineSpermineStereoisomerismStructure-Activity RelationshipTemperatureTumor Cells, CulturedConceptsDinuclear platinum compoundsPt–Cl bondsPreliminary biological assaysN-butyl side chainsMagnitude less cytotoxicPolynuclear platinumSecond generation analogsNMR spectroscopyPolyamine linkersQuaternary nitrogenFMOC derivativesConformational isomersDerivatives 4Electrostatic contributionSide chainsHydrolytic cleavageSpermidine moietyGreater selectivityOral deliveryTherapeutic indexPlatinum drugsRate constantsCellular uptakeN-propylBiological assays
1994
Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon
Roberts J, Bigelow J, Moore A, Belinson J, Stewart J, Hacker M. Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon. Journal Of Immunotherapy 1994, 15: 53-58. PMID: 8110731, DOI: 10.1097/00002371-199401000-00007.Peer-Reviewed Original ResearchMeSH KeywordsBiopterinFemaleHumansInfusions, ParenteralInterleukin-2Killer Cells, Lymphokine-ActivatedMelanomaNeopterinOvarian NeoplasmsConceptsLymphokine-activated killer cellsNeopterin productionInterleukin-2Killer cellsIntraperitoneal interleukin-2Killer cell phenomenonUrinary neopterin excretionRoute of administrationActivated T cellsPresence of neopterinNumber of cytokinesLack of effectN-acetyl serotoninIncreased SystemicNeopterin excretionOvarian carcinomaT cellsImmune responseClinical administrationNeopterinCytotoxic effectsAdministrationSynthesis inhibitorCell phenomenonCells
1992
Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
Farrell N, Kelland LR, Roberts JD, Van Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Research 1992, 52: 5065-72. PMID: 1516063.Peer-Reviewed Original ResearchConceptsPlatinum antitumor complexesPlanar ligandsPyridine complexesAmmine complexesAntitumor complexesNew trans platinum complexesCell linesHuman tumor cell linesTrans-platinum complexesTumor cell linesPreliminary mechanistic studiesMurine L1210Rate of reactionFormula transMechanism of actionTrans complexesTrans geometryImportant biomoleculesSteric hindranceThymus DNAHuman tumor panelOvarian carcinoma cell linesCarcinoma cell linesPotential new classDNA synthesis
1990
Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research 1990, 50: 6302-10. PMID: 2205379.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsRecombinant interleukin-2LAK activityIL-2Killer cellsDose levelsMononuclear cellsUnits/m2 body surface areaIntraperitoneal recombinant interleukin-2M2 body surface areaLAK/ILOvarian cancer refractorySerum IL-2Less IL-2Dose-limiting toxicityPhase I trialIL-2 levelsAdditional IL-2IL-2-dependent cell lineBody surface areaSignificant weight gainMononuclear cell collectionPeripheral blood cellsHighest dose levelCancer refractory